Skip to main content
79°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
42.87
+0.23 (+0.54%)
Streaming Delayed Price
Updated: 11:31 AM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer
March 21, 2024
The European Commission approved Bristol Myers Squibb's Abecma for relapsed/refractory multiple myeloma, making it the first CAR T cell therapy endorsed in the EU for earlier treatment lines.
Via
Benzinga
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
March 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...
Via
Benzinga
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
March 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Check Out What Whales Are Doing With BMY
March 19, 2024
Via
Benzinga
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
March 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Why NYSE:BMY is a Top Pick for Dividend Investors.
March 12, 2024
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing?
Via
Chartmill
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
March 11, 2024
Via
Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
March 04, 2024
Via
Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
March 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
March 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
March 15, 2024
FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of...
Via
Benzinga
Exposures
Product Safety
What's Going On With Cancer Focused-Geron Stock On Friday?
March 15, 2024
Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date....
Via
Benzinga
Exposures
Product Safety
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
March 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...
Via
Benzinga
Exposures
Product Safety
Be A Smart Investor – Don’t Hold On For Dear Life
March 13, 2024
You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months.
Via
Talk Markets
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
March 11, 2024
From
Bristol Myers Squibb
Via
Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
March 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
March 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town
March 06, 2024
Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors.
Via
InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
Bristol Myers Squibb Announces Dividend
March 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
February 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.